UK markets closed
  • NIKKEI 225

    27,819.33
    -180.63 (-0.65%)
     
  • HANG SENG

    20,082.43
    +471.59 (+2.40%)
     
  • CRUDE OIL

    94.36
    +2.43 (+2.64%)
     
  • GOLD FUTURES

    1,806.70
    -7.00 (-0.39%)
     
  • DOW

    33,491.05
    +181.54 (+0.55%)
     
  • BTC-GBP

    19,959.93
    +272.55 (+1.38%)
     
  • CMC Crypto 200

    576.50
    +1.76 (+0.31%)
     
  • ^IXIC

    12,870.54
    +15.73 (+0.12%)
     
  • ^FTAS

    4,131.26
    -19.42 (-0.47%)
     

Global Proteomics Partnering Terms and Agreements Deals Report/Directory 2021: Trends, Players and Financials for 550+ Deals Records 2014-2021 - ResearchAndMarkets.com

·4-min read

DUBLIN, December 03, 2021--(BUSINESS WIRE)--The "Global Proteomics Partnering Terms and Agreements 2010 to 2021" report has been added to ResearchAndMarkets.com's offering.

The Global Proteomics Partnering Terms and Agreements 2010 to 2021 report provides an understanding and access to the Proteomics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Proteomics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Proteomics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual Proteomics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Proteomics technologies and products.

Report Scope

Global Proteomics Partnering Terms and Agreements 2010 to 2021 includes:

  • Trends in Proteomics dealmaking in the biopharma industry since 2010

  • Access to headline, upfront, milestone and royalty data

  • Access to over 550 Proteomics deal records and contract documents where available

  • The leading antibody deals by value since 2010

  • Most active Proteomics dealmakers since 2010

  • The leading Proteomics partnering resources

In Global Proteomics Partnering Terms and Agreements 2010 to 2021, the available contracts are listed by:

  • Company A-Z

  • Headline value

  • Stage of development at signing

  • Deal component type

  • Specific therapy and technology target

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Proteomics dealmaking

2.1. Introduction

2.2. Proteomics partnering over the years

2.3. Most active Proteomics dealmakers

2.4. Proteomics partnering by deal type

2.5. Proteomics partnering by therapy area

2.6. Deal terms for Proteomics partnering

2.6.1 Proteomics partnering headline values

2.6.2 Proteomics deal upfront payments

2.6.3 Proteomics deal milestone payments

2.6.4 Proteomics royalty rates

Chapter 3 - Leading Proteomics deals

3.1. Introduction

3.2. Top Proteomics deals by value

Chapter 4 - Most active Proteomics dealmakers

4.1. Introduction

4.2. Most active Proteomics dealmakers

4.3. Most active Proteomics partnering company profiles

Chapter 5 - Proteomics contracts dealmaking directory

5.1. Introduction

5.2. Proteomics contracts dealmaking directory

Chapter 6 - Proteomics dealmaking by technology type

Chapter 7 - Partnering resource center

7.1. Online partnering

7.2. Partnering events

7.3. Further reading on dealmaking

Appendices

Appendix 1 - Proteomics deals by company A-Z

Appendix 2 - Proteomics deals by stage of development

Appendix 3 - Proteomics deals by deal type

Appendix 4 - Proteomics deals by therapy area

Appendix 5 - Deal type definitions

Companies Mentioned

  • Magellan Biosciences

  • Waters Corporation

  • Signalchem

  • WaferGen Biosystems

  • Integrated Biobank of Luxembourg

  • Nonlinear Dynamics

  • Abt Bio Pharma Solutions

  • Xencor

  • Esperion Therapeutics

  • Sengenics

  • University of Hamburg

  • Gritstone Oncology

  • Fraunhofer USA Center for Molecular Biotechnology

  • Inverness Medical Innovations

  • 3SBio

  • Vifor Pharma

  • Targeted Payload Therapeutics

  • Biotage

  • Monsanto

  • Global Centers for Therapeutic Innovation

  • PPD

  • Novartis Molecular Diagnostics

  • Radiation Control Technologies

  • Adimab

  • AstraZeneca

  • Mariel Therapeutics

  • Intavis Bioanalytical Instruments

  • Thermo Fisher Scientific

  • University of Western Australia

  • DiscoveryBioMed

  • John Hopkins University School of Medicines

  • Genzyme

  • European Foundation For The Study Of Diabetes

  • Stratose

  • ACGT

  • Smart Personalized Medicine

  • PROLOR Biotech

  • SomaLogic

  • BioSystem Development

  • Maine Manufacturing

  • PhileKorea

  • AEterna Zentaris

  • Biomodels

  • Protiva Biotherapeutics

  • KGH Domestic

  • University of Oxford

  • Minapharm

  • American Health Assistance Foundation

  • Pharm Tech Korea

  • Pepscan

For more information about this report visit https://www.researchandmarkets.com/r/nygc2s

View source version on businesswire.com: https://www.businesswire.com/news/home/20211203005271/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting